NEW YORK, Feb. 5 - MDS Proteomics has acquired roughly 2,000 disease-related, full-length cDNA clones from Japan's Kazusa DNA Research Institute, MDS said on Tuesday.
The three-year deal "is a major step" to help MDS meet its goal of discovering 1,000 new drug targets in the next five years, according to Frank Gleeson, president and CEO of MDS Proteomics.
Financial terms of the agreement were not disclosed.
"This is a further demonstration that MDS Proteomics has moved aggressively to apply its platform to discover new treatments for human diseases," the company said in a statement.
Last month, MDS and rival proteomics firm Cellzome made substantial strides in decoding the yeast proteome. From MDS' side, researchers converted about 10 percent of the yeast genome into bait proteins and detected 3,617 protein interactions. The team identified more than 25 percent of the yeast proteome, including more than 500 new proteins, in a matter of weeks.